NICE updated the process for providing scientific advice on December 2022. We describe these changes and how we can support you through this process.
By Mai Ping Tan, PhD - Value Communications Consultant
Why would companies seek scientific advice from NICE?
As the HTA agency for the NHS in England, NICE can offer a fee-based advisory service to provide their point of view on a company's evidence plan to support the appraisal for a new technology
This ultimately helps companies understand whether their evidence package and planned evidence generation plans are likely to be sufficient in helping gain patient access in the UK
What has changed in December 2022?
A single “set” scientific advice process will replace the existing standard or express routes
Simplified process with receipt of final advice by Week 15 (vs Week 20 for standard route and Week 12 for express route)
No change to advice meeting or report
Further tweaks are expected to follow
What other forms of scientific advice can NICE offer?
Office for Market Access: helping companies engage with NICE and the healthcare system to speed up market access
Preliminary Independent Model Advice (PRIMA) service: advice to improve quality of health economic models
Parallel advice with other agencies:
How can RJW&partners help?
To learn more
Visit NICE set scientific advice , or get in touch with the RJW&partners team for an informal chat.